Talaska G, Jaeger M, Reilman R, Collins T, Warshawsky D
Department of Environmental Health, University of Cincinnati, OH 45267-0056, USA.
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7789-93. doi: 10.1073/pnas.93.15.7789.
Carcinogen-DNA adduct measurements may become useful biomarkers of effective dose and/or early effect. However, validation of this biomarker is required at several levels to ensure that human exposure and response are accurately reflected. Important in this regard is an understanding of the relative biomarker levels in target and nontarget organs and the response of the biomarker under the chronic, low-dose conditions to which humans are exposed. We studied the differences between single and chronic topical application of benzo[a]pyrene (BAP) on the accumulation and removal of BAP-DNA adducts in skin, lung, and liver. Animals were treated with BAP at 10, 25, or 50 nMol topically once or twice per week for as long as 15 weeks. Animals were sacrificed either at 24, 48, or 72 hr after the last dose at 1 and 30 treatments, and after 24 hr for all other treatment groups. Adduct levels increased with increasing dose, but the slope of the dose-response was different in each organ. At low doses, accumulation was linear in skin and lung, but at high doses the adduct levels in the lung increased dramatically at the same time when the levels in the skin reached apparent steady state. In the liver adduct, levels were lower than in target tissues and apparent steady-state adduct levels were reached rapidly, the maxima being independent of dose, suggesting that activating metabolism was saturated in this organ. Removal of adducts from skin, the target organ, was more rapid following single treatment than with chronic exposure. This finding is consistent with earlier data, indicating that some areas of the genome are more resistant to repair. Thus, repeated exposure and repair cycles would be more likely to cause an increase in the proportion of carcinogen-DNA adducts in repair-resistant areas of the genome. These findings indicate that single-dose experiments may underestimate the potential for carcinogenicity for compounds that follow this pattern.
致癌物 - DNA加合物测量可能成为有效剂量和/或早期效应的有用生物标志物。然而,需要在多个层面验证这种生物标志物,以确保准确反映人类暴露情况和反应。在这方面,了解目标器官和非目标器官中生物标志物的相对水平以及该生物标志物在人类所接触的慢性低剂量条件下的反应非常重要。我们研究了单次和长期局部应用苯并[a]芘(BAP)对皮肤、肺和肝脏中BAP - DNA加合物积累和清除的影响。动物每周接受10、25或50 nMol的BAP局部治疗一次或两次,持续长达15周。在第1次和第30次治疗的最后一剂后24、48或72小时处死动物,其他所有治疗组在最后一剂后24小时处死。加合物水平随剂量增加而升高,但各器官中剂量反应的斜率不同。在低剂量时,皮肤和肺中的积累呈线性,但在高剂量时,当皮肤中的加合物水平达到明显稳定状态时,肺中的加合物水平急剧增加。肝脏中的加合物水平低于目标组织,且迅速达到明显的稳定状态加合物水平,最大值与剂量无关,这表明该器官中的激活代谢已饱和。单次治疗后,目标器官皮肤中加合物的清除比长期暴露后更快。这一发现与早期数据一致,表明基因组的某些区域对修复更具抗性。因此,重复暴露和修复循环更有可能导致基因组中抗修复区域的致癌物 - DNA加合物比例增加。这些发现表明,单剂量实验可能低估了遵循这种模式的化合物的致癌潜力。